The most common adverse events in the treatment phase were injection-site reaction ( no patients with placebo vs three patients with 0.33 MIU and 1 MIU vs two patients with 3 MIU ) and influenza-like syndrome ( no patients with placebo vs one patient with 0.33 MIU and 1 MIU vs four patients with 3 MIU ) .